Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

PP405 and JXL-069 are the same compound, but users experienced no results due to flawed application methods. The topical gel formulation of PP405 is designed to target hair follicle stem cells effectively, unlike liquid solutions that fail to penetrate deeply.

PP405 is expected to work for hair regrowth by reactivating stem cells in hair follicles, with FDA approval anticipated in 2027-28. Users express both optimism and skepticism about its effectiveness and the lengthy approval process.

Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.

A user is attempting to reformulate a topical gel using PP-405 for hair loss, aiming to enhance its effectiveness with additional compounds. They discuss the potential of PP-405 compared to other treatments like Minoxidil and GT20029, and emphasize the importance of proper formulation for efficacy.

A user shared their 4-month progress using oral finasteride and minoxidil, reporting significant hair regrowth with no noticeable side effects. They used a blend from HIMS, including additional vitamins and minerals, and addressed concerns about lighting differences in photos.

A 29-year-old is using liposomal topical finasteride/minoxidil and low-level light therapy (LLLT) to improve hair growth, showing significant progress in crown recovery. The user prefers liposomal topicals to avoid side effects from oral finasteride and uses the iRestore Essential device for LLLT.

A user shared their 4-month progress using a topical solution with 5% minoxidil and 0.1% finasteride, applied twice daily. They reported good results despite occasional missed applications.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

Scientists found hidden stem cells that might reactivate hair growth. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

The conversation is about interest in watching the Pelage PP405 presentation online, with mentions of hair loss treatments like finasteride. Users express frustration and humor about the topic, with one user noting finasteride caused discomfort.

Topical application of Eriodictyon angustifolium extract can prevent and reverse age-related beard graying and darken gray hair by increasing melanin production. Sterubin, a component of the extract, also promotes hair pigmentation and protects cells from DNA damage.

The user has been taking 1mg finasteride daily and is seeking opinions on hair progress, but inconsistent lighting in photos makes it hard to judge. Some users suggest there might be slight improvement and recommend adding minoxidil for better results.

The Brighton FC coach's drastic hair change is speculated to be due to a hair system or transplant, with some suggesting he might have stopped using Minoxidil. Opinions vary on whether he had a transplant, wore a wig, or if the photos were mislabeled.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.

Amplifica is developing new molecules for hair growth, with clinical trials expected soon, while Engraft Technologies is improving FUE robotic technology to make hair transplants faster and cheaper. Users express interest in the timeline for AMP-303 and concerns about high costs and effectiveness of current treatments.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The user experienced good hair regrowth using natural methods and mechanical stimulation but decided to add finasteride to their regimen for better results. They are optimistic about further regrowth and plan to update on the effects of finasteride, noting no significant side effects so far.

Noxidil from Zeemoreuncle appears legitimate based on a bleach test with oral minoxidil tablets. The test results showed an instant color change, suggesting the product's authenticity.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

OP noticed fuller and thicker hair after almost 4 months of using GHK-Cu, a copper-binding peptide, through subcutaneous injections. Some users were skeptical, questioning the authenticity and potential commercial intent behind the post.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.

The conversation is about a user experiencing positive hair regrowth results after using finasteride, minoxidil spray, dermapen, and low-level light therapy (LLLT) for four months. The user recommends using a specific device for LLLT and mentions using the Hims spray for finasteride and minoxidil.

RU58841 and topical GHK-CU are used together for hair loss, with RU58841 reducing shedding and GHK-CU improving scalp health. Users report noticeable hair growth and improved hair quality within weeks, especially when used consistently.

The conversation discusses using daily microneedling at 0.25mm and red light therapy to enhance hair regrowth, especially when traditional treatments like finasteride and minoxidil become less effective. The combination is said to improve hair density and thickness, with red light therapy being more cosmetic, while microneedling is essential for challenging areas.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.